Skip to content
OpenCapital
Get started

Lexicon Pharmaceuticals LXRX Share-based compensation expense related to employee stock plans

Share-based compensation expense related to employee stock plans at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——

Other financials

Income statement

See full
Revenue$21.1M+1,572%
Gross profit$21.0M+1,604%
Operating income-$996.0K+96.1%
Net income-$1.0M+95.9%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$67.1M+6.7%
Total debt$57.7M-45.7%
Total equity$202.9M+64.9%
Total assets$268.8M-9.7%

Cash flow

See full
Operating cash flow-$14.7M+66.4%
CapEx--100%
Free cash flow-$17.2M+21.5%

Valuation

See full
Market cap$986.12M+273%
Enterprise value$976.73M+219%
P/S14.2×+5.7×

Profitability

See full
Gross margin99.5%+1.5pp
Operating margin-34.8%-16.8pp
Net margin-37.5%-18.1pp
FCF margin-578.5%-283pp

Returns & leverage

See full
Return on equity-16%-7.2pp
Debt / equity0.3×-0.6×
Current ratio18.8×+16.6×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lexicon Pharmaceuticals's share-based compensation expense related to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lexicon Pharmaceuticals's share-based compensation expense related to employee stock plans?
Lexicon Pharmaceuticals (LXRX) reported share-based compensation expense related to employee stock plans of $3.08M in Q1 2026.
How has Lexicon Pharmaceuticals's share-based compensation expense related to employee stock plans changed year-over-year?
Lexicon Pharmaceuticals's share-based compensation expense related to employee stock plans increased by 1.2% year-over-year, from $3.04M to $3.08M.
What is the long-term trend for Lexicon Pharmaceuticals's share-based compensation expense related to employee stock plans?
Over 4 years (2021 to 2025), Lexicon Pharmaceuticals's share-based compensation expense related to employee stock plans has grown at a 4.3% compound annual growth rate (CAGR), from $10.58M to $12.52M.